TEVA's recent correction reflected the analysts/big boys being able to monitor the slightly disappointing revenue growth. What we see today, that they couldn't as easily follow, is the continued improved performance. Another $500 Million lopped off the net debt this quarter, now down to $22.7 Billion. Reaffirmed FCF guidance of 2.0-2.3 Billion will continue this deleveraging. That's \/SHARE"}==!>, which equates to an increase in intrinsic value of TEVA stock of $2 plus perhaps another $2 from the de-risking that entails. That's quite a nice % increase on the current low stock price.Buy Teva. $TEVA, Teva Pharmaceutical Industries Limited / H1